Raxibacumab

What is this medication?

Raxibacumab is a specialized monoclonal antibody used to treat and prevent inhalational anthrax, a severe and potentially life-threatening condition caused by breathing in Bacillus anthracis spores. This medication is approved for use in both adults and children who have been exposed to the bacteria or are already showing symptoms of the disease. It is often administered in combination with appropriate antibiotic medications to provide a comprehensive approach to fighting the infection and its systemic effects.

The medication works by targeting and neutralizing the toxins produced by the anthrax bacteria rather than attacking the bacteria themselves. Specifically, raxibacumab binds to the protective antigen of the anthrax toxin, which prevents the toxin from entering and damaging the body's cells. By blocking this pathway, the drug helps to stop the progression of the disease and increases the chances of survival. It is typically delivered as a single dose through an intravenous infusion in a clinical setting.